{"id":"https://openalex.org/W7223847876","doi":"https://doi.org/10.1111/jvh.70246","title":"A Randomized, Double\u2010Blind, Placebo\u2010Controlled Study of the PD\u20101 Inhibitor Cetrelimab in Chronic Hepatitis B","display_name":"A Randomized, Double\u2010Blind, Placebo\u2010Controlled Study of the PD\u20101 Inhibitor Cetrelimab in Chronic Hepatitis B","publication_year":2026,"publication_date":"2026-10-26","ids":{"openalex":"https://openalex.org/W7223847876","doi":"https://doi.org/10.1111/jvh.70246","pmid":"https://pubmed.ncbi.nlm.nih.gov/42934895","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/13710783"},"language":"en","primary_location":{"id":"doi:10.1111/jvh.70246","doi":"https://doi.org/10.1111/jvh.70246","is_oa":true,"landing_page_url":"https://doi.org/10.1111/jvh.70246","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jvh.70246","source":{"id":"https://openalex.org/S164225461","display_name":"Journal of Viral Hepatitis","issn_l":"1352-0504","issn":["1352-0504","1365-2893"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Viral Hepatitis","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jvh.70246","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5009032052","display_name":"Tarik Asselah","orcid":"https://orcid.org/0000-0002-0024-0595","observed_orcids":["https://orcid.org/0000-0002-0024-0595"]},"institutions":[{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I204730241","display_name":"Universit\u00e9 Paris Cit\u00e9","ror":"https://ror.org/05f82e368","country_code":"FR","type":"education","lineage":["https://openalex.org/I204730241"]},{"id":"https://openalex.org/I2799502834","display_name":"H\u00f4pital Beaujon","ror":"https://ror.org/03jyzk483","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I2799502834","https://openalex.org/I4210097159"]}],"countries":["FR"],"is_corresponding":true,"raw_author_name":"Tarik Asselah","raw_affiliation_strings":["Department of Hepatology, AP\u2010HP H\u00f4pital Beaujon Universit\u00e9 de Paris\u2010Cit\u00e9, INSERM UMR1149  Clichy France"],"raw_orcid":"https://orcid.org/0000-0002-0024-0595","affiliations":[{"raw_affiliation_string":"Department of Hepatology, AP\u2010HP H\u00f4pital Beaujon Universit\u00e9 de Paris\u2010Cit\u00e9, INSERM UMR1149  Clichy France","institution_ids":["https://openalex.org/I154526488","https://openalex.org/I204730241","https://openalex.org/I2799502834"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088020835","display_name":"Thomas N. Kakuda","orcid":"https://orcid.org/0000-0001-6857-2572","observed_orcids":["https://orcid.org/0000-0001-6857-2572"]},"institutions":[{"id":"https://openalex.org/I1330063522","display_name":"Johnson & Johnson (United States)","ror":"https://ror.org/03qd7mz70","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Thomas N. Kakuda","raw_affiliation_strings":["Johnson & Johnson  San Diego California USA"],"raw_orcid":"https://orcid.org/0000-0001-6857-2572","affiliations":[{"raw_affiliation_string":"Johnson & Johnson  San Diego California USA","institution_ids":["https://openalex.org/I1330063522"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061859093","display_name":"Sarah F. Kulke","orcid":"https://orcid.org/0000-0001-5922-8761","observed_orcids":["https://orcid.org/0000-0001-5922-8761"]},"institutions":[{"id":"https://openalex.org/I1330063522","display_name":"Johnson & Johnson (United States)","ror":"https://ror.org/03qd7mz70","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sarah Kulke","raw_affiliation_strings":["Johnson & Johnson  San Diego California USA"],"raw_orcid":"https://orcid.org/0000-0001-5922-8761","affiliations":[{"raw_affiliation_string":"Johnson & Johnson  San Diego California USA","institution_ids":["https://openalex.org/I1330063522"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080561801","display_name":"Evelyn Walenta","orcid":"https://orcid.org/0009-0008-7732-080X","observed_orcids":["https://orcid.org/0009-0008-7732-080X"]},"institutions":[{"id":"https://openalex.org/I1330063522","display_name":"Johnson & Johnson (United States)","ror":"https://ror.org/03qd7mz70","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Evelyn Walenta","raw_affiliation_strings":["Johnson & Johnson  San Diego California USA"],"raw_orcid":"https://orcid.org/0009-0008-7732-080X","affiliations":[{"raw_affiliation_string":"Johnson & Johnson  San Diego California USA","institution_ids":["https://openalex.org/I1330063522"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059524470","display_name":"Robin J. Halter","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1330063522","display_name":"Johnson & Johnson (United States)","ror":"https://ror.org/03qd7mz70","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robin J. Halter","raw_affiliation_strings":["Johnson & Johnson  San Diego California USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Johnson & Johnson  San Diego California USA","institution_ids":["https://openalex.org/I1330063522"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082642164","display_name":"Jay Ariyawansa","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jay Ariyawansa","raw_affiliation_strings":["Johnson & Johnson  Raritan New Jersey USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Johnson & Johnson  Raritan New Jersey USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043726043","display_name":"Simon Verheijden","orcid":"https://orcid.org/0000-0002-6523-6837","observed_orcids":["https://orcid.org/0000-0002-6523-6837"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Simon Verheijden","raw_affiliation_strings":["Johnson & Johnson  Beerse Belgium"],"raw_orcid":"https://orcid.org/0000-0002-6523-6837","affiliations":[{"raw_affiliation_string":"Johnson & Johnson  Beerse Belgium","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031660163","display_name":"Oliver Lenz","orcid":"https://orcid.org/0009-0006-4942-6557","observed_orcids":["https://orcid.org/0009-0006-4942-6557"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Oliver Lenz","raw_affiliation_strings":["Johnson & Johnson  Beerse Belgium"],"raw_orcid":"https://orcid.org/0009-0006-4942-6557","affiliations":[{"raw_affiliation_string":"Johnson & Johnson  Beerse Belgium","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017013892","display_name":"Zuleima Aguilar","orcid":"https://orcid.org/0009-0001-2927-0130","observed_orcids":["https://orcid.org/0009-0001-2927-0130"]},"institutions":[{"id":"https://openalex.org/I1330063522","display_name":"Johnson & Johnson (United States)","ror":"https://ror.org/03qd7mz70","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Zuleima Aguilar","raw_affiliation_strings":["Johnson & Johnson  San Diego California USA"],"raw_orcid":"https://orcid.org/0009-0001-2927-0130","affiliations":[{"raw_affiliation_string":"Johnson & Johnson  San Diego California USA","institution_ids":["https://openalex.org/I1330063522"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002507814","display_name":"Isabelle Lonjon\u2010Domanec","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Isabelle Lonjon\u2010Domanec","raw_affiliation_strings":["Johnson & Johnson  Beerse Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Johnson & Johnson  Beerse Belgium","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5044004813","display_name":"Michael Biermer","orcid":"https://orcid.org/0000-0001-6993-8206","observed_orcids":["https://orcid.org/0000-0001-6993-8206"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Michael Biermer","raw_affiliation_strings":["Johnson & Johnson  Beerse Belgium"],"raw_orcid":"https://orcid.org/0000-0001-6993-8206","affiliations":[{"raw_affiliation_string":"Johnson & Johnson  Beerse Belgium","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5009032052"],"corresponding_institution_ids":["https://openalex.org/I154526488","https://openalex.org/I204730241","https://openalex.org/I2799502834"],"apc_list":{"value":4610,"currency":"USD","value_usd":4610},"apc_paid":{"value":4610,"currency":"USD","value_usd":4610},"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.86310976,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"33","issue":"11","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10340","display_name":"Hepatitis B Virus Studies","score":0.9945999979972839,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10340","display_name":"Hepatitis B Virus Studies","score":0.9945999979972839,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10151","display_name":"Hepatitis C virus research","score":0.0017999999690800905,"subfield":{"id":"https://openalex.org/subfields/2721","display_name":"Hepatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.0012000000569969416,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/chronic-hepatitis-b","display_name":"chronic hepatitis B","score":0.9459999799728394},{"id":"https://openalex.org/keywords/pd-1-inhibitors","display_name":"PD-1 inhibitors","score":0.8339999914169312},{"id":"https://openalex.org/keywords/t-cell-exhaustion","display_name":"T cell exhaustion","score":0.9200000166893005},{"id":"https://openalex.org/keywords/virologically-suppressed","display_name":"virologically suppressed","score":0.6980000138282776},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9549999833106995},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.6179999709129333},{"id":"https://openalex.org/keywords/hepatitis-b-reactivation","display_name":"HBV reactivation","score":0.7480000257492065},{"id":"https://openalex.org/keywords/monoclonal-antibodies","display_name":"monoclonal antibodies","score":0.6470000147819519}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.891700029373169},{"id":"https://openalex.org/C2780593183","wikidata":"https://www.wikidata.org/wiki/Q6844","display_name":"Hepatitis B virus","level":3,"score":0.6229000091552734},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.617900013923645},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5999000072479248},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.5593000054359436},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.557200014591217},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.5389999747276306},{"id":"https://openalex.org/C3020491458","wikidata":"https://www.wikidata.org/wiki/Q131742","display_name":"Chronic hepatitis","level":3,"score":0.5338000059127808},{"id":"https://openalex.org/C2777382497","wikidata":"https://www.wikidata.org/wiki/Q6853","display_name":"Hepatitis B","level":2,"score":0.4837000072002411},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.4596000015735626},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.42559999227523804},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.41130000352859497},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.4083000123500824},{"id":"https://openalex.org/C2992208098","wikidata":"https://www.wikidata.org/wiki/Q1359801","display_name":"Liver function","level":2,"score":0.3873000144958496},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3325999975204468},{"id":"https://openalex.org/C201903717","wikidata":"https://www.wikidata.org/wiki/Q1778788","display_name":"Cohort study","level":2,"score":0.31369999051094055},{"id":"https://openalex.org/C2776029263","wikidata":"https://www.wikidata.org/wiki/Q131742","display_name":"Hepatitis","level":2,"score":0.30160000920295715},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.29499998688697815},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.27630001306533813},{"id":"https://openalex.org/C3018359032","wikidata":"https://www.wikidata.org/wiki/Q1550789","display_name":"Safety profile","level":3,"score":0.2678999900817871},{"id":"https://openalex.org/C2522874641","wikidata":"https://www.wikidata.org/wiki/Q808","display_name":"Virus","level":2,"score":0.26440000534057617},{"id":"https://openalex.org/C502991105","wikidata":"https://www.wikidata.org/wiki/Q5133849","display_name":"Clinical research","level":2,"score":0.2628999948501587},{"id":"https://openalex.org/C512861765","wikidata":"https://www.wikidata.org/wiki/Q1359801","display_name":"Liver function tests","level":2,"score":0.2508000135421753}],"mesh":[{"descriptor_ui":"D000082082","descriptor_name":"Immune Checkpoint Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000082082","descriptor_name":"Immune Checkpoint Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000082082","descriptor_name":"Immune Checkpoint Inhibitors","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D000082082","descriptor_name":"Immune Checkpoint Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000998","descriptor_name":"Antiviral Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000998","descriptor_name":"Antiviral Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000998","descriptor_name":"Antiviral Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D000998","descriptor_name":"Antiviral Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006515","descriptor_name":"Hepatitis B virus","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007279","descriptor_name":"Injections, Subcutaneous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019694","descriptor_name":"Hepatitis B, Chronic","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D061026","descriptor_name":"Programmed Cell Death 1 Receptor","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":3,"locations":[{"id":"doi:10.1111/jvh.70246","doi":"https://doi.org/10.1111/jvh.70246","is_oa":true,"landing_page_url":"https://doi.org/10.1111/jvh.70246","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jvh.70246","source":{"id":"https://openalex.org/S164225461","display_name":"Journal of Viral Hepatitis","issn_l":"1352-0504","issn":["1352-0504","1365-2893"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Viral Hepatitis","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:13710783","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13710783/","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13710783/pdf/JVH-33-0.pdf","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"J Viral Hepat","raw_type":"Text"},{"id":"pmid:42934895","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/42934895","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of viral hepatitis","raw_type":"Clinical Trial, Phase I"}],"best_oa_location":{"id":"doi:10.1111/jvh.70246","doi":"https://doi.org/10.1111/jvh.70246","is_oa":true,"landing_page_url":"https://doi.org/10.1111/jvh.70246","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jvh.70246","source":{"id":"https://openalex.org/S164225461","display_name":"Journal of Viral Hepatitis","issn_l":"1352-0504","issn":["1352-0504","1365-2893"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Viral Hepatitis","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Randomized Controlled Trial","id":"https://openalex.org/study-designs/randomized-controlled-trial"},{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320332194","display_name":"Johnson and Johnson","ror":"https://ror.org/03qd7mz70"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7223847876.pdf","grobid_xml":"https://content.openalex.org/works/W7223847876.grobid-xml"},"referenced_works_count":24,"referenced_works":["https://openalex.org/W1983251878","https://openalex.org/W2099609050","https://openalex.org/W2160834915","https://openalex.org/W2183144139","https://openalex.org/W2605785536","https://openalex.org/W2810928105","https://openalex.org/W2962219096","https://openalex.org/W2989703635","https://openalex.org/W3017499363","https://openalex.org/W3031206422","https://openalex.org/W4200217608","https://openalex.org/W4220710445","https://openalex.org/W4220999200","https://openalex.org/W4283217337","https://openalex.org/W4313546245","https://openalex.org/W4386588189","https://openalex.org/W4387521848","https://openalex.org/W4389740232","https://openalex.org/W4391926845","https://openalex.org/W4392014306","https://openalex.org/W4400406254","https://openalex.org/W4401100726","https://openalex.org/W4410163238","https://openalex.org/W7165401749"],"related_works":["https://openalex.org/W7117106125","https://openalex.org/W2962219096","https://openalex.org/W2056052081","https://openalex.org/W2366488253","https://openalex.org/W2297701991","https://openalex.org/W3110380055","https://openalex.org/W7097330391","https://openalex.org/W1995915978","https://openalex.org/W3031957322","https://openalex.org/W231105904"],"abstract_inverted_index":{"Hepatitis":[0],"B":[1,52],"virus":[2],"(HBV)-induced":[3],"T-cell":[4],"exhaustion":[5],"may":[6],"be":[7],"reversed":[8],"using":[9],"a":[10,38,58,78],"programmed":[11],"death":[12],"receptor":[13,110],"1":[14],"(PD-1)":[15],"inhibitor":[16],"such":[17],"as":[18],"cetrelimab,":[19],"an":[20],"investigational":[21],"fully":[22],"human":[23],"monoclonal":[24],"antibody":[25],"targeting":[26],"PD-1.":[27],"To":[28],"evaluate":[29],"the":[30,137],"safety,":[31],"activity":[32],"and":[33,81,113,124,129,133,182,208,218],"pharmacokinetics":[34],"of":[35,70,197,221],"low-dose":[36],"(i.e.,":[37],"dose":[39,196],"lower":[40],"than":[41],"that":[42],"used":[43],"in":[44,47,172,201,215],"oncology)":[45],"cetrelimab":[46,71,105,128,140,150,198,222],"participants":[48,121,203],"with":[49,145,204],"chronic":[50],"hepatitis":[51],"(CHB)":[53],"virologically":[54],"suppressed":[55],"(VS)":[56],"on":[57],"stable":[59],"nucleos(t)ide":[60],"analog":[61],"(NA).":[62],"Randomized,":[63],"double-blind,":[64],"placebo-controlled,":[65],"multi-cohort,":[66],"single-dose":[67],"escalation":[68],"study":[69],"administered":[72,199],"subcutaneously":[73,200],"or":[74,175],"intravenously.":[75],"Due":[76],"to":[77,83,100,127,131,148],"strategic":[79],"decision,":[80],"not":[82],"any":[84],"safety":[85,114],"concern,":[86],"only":[87],"one":[88],"cohort":[89],"(45":[90],"mg":[91,195],"subcutaneous)":[92],"was":[93,142,157,206,212,225],"executed.":[94],"Participants":[95],"maintained":[96],"their":[97],"NA":[98],"treatment":[99],"avoid":[101],"HBV":[102,107,173,216,224],"reactivation.":[103],"Serum":[104],"concentrations,":[106],"biomarkers,":[108],"PD-1":[109],"occupancy":[111],"(RO)":[112],"were":[115,122,167,190],"collected":[116],"over":[117,164],"24":[118],"weeks.":[119],"Eleven":[120],"enrolled":[123],"randomized,":[125],"eight":[126],"three":[130],"placebo":[132],"all":[134],"11":[135],"completed":[136],"study.":[138],"Mean":[139],"half-life":[141],"16.3":[143],"days":[144,153],"median":[146],"time":[147],"maximum":[149],"concentration":[151],"10.4":[152],"post-dose.":[154],"Near-maximal":[155],"RO":[156],"achieved":[158],"6":[159],"h":[160],"post-dose":[161],"which":[162],"waned":[163],"time.":[165],"There":[166,211],"no":[168,213],"clinically":[169,186],"relevant":[170,187],"changes":[171],"biomarkers":[174,217],"laboratory":[176],"values":[177],"including":[178],"liver":[179],"function":[180],"tests":[181],"thyroid-stimulating":[183],"hormone.":[184],"No":[185],"adverse":[188],"events":[189],"reported.":[191],"A":[192],"single":[193],"45":[194],"VS":[202],"CHB":[205],"safe":[207],"well":[209],"tolerated.":[210],"change":[214],"further":[219],"development":[220],"for":[223],"abandoned.":[226],"Clinical":[227],"Trial":[228],"Registration:":[229],"ClinicalTrials.gov:":[230],"NCT05242445;":[231],"EudraCT":[232],"Number:":[233],"2021-004857-21.":[234]},"counts_by_year":[],"updated_date":"2026-11-01T11:40:01.658920","created_date":"2026-10-28T00:00:00"}